Jun 18, 2013

Posted by in Featured, Stock Market News | 0 Comments

Volatile Movements – Canadian Solar Inc. (NASDAQ:CSIQ), AK Steel Holding Corporation (NYSE:AKS), Dynavax Technologies Corporation (NASDAQ:DVAX)

Volatile Movements – Canadian Solar Inc. (NASDAQ:CSIQ), AK Steel Holding Corporation (NYSE:AKS), Dynavax Technologies Corporation (NASDAQ:DVAX)

Canadian Solar Inc. (NASDAQ:CSIQ) moved up +7.66% and closed at $10.12 in the last trading session, with the overall traded volume of 7.35 million shares. Stock price 52 weeks high was $10.65 and 52 weeks low price was $1.95. CSIQ has market cap of 436.74 million. Canadian Solar Inc. (CSI) designs, develops, and manufactures solar wafers, cells and solar module products that convert sunlight into electricity for a variety of uses. The Company’s products include a range of standard solar modules built to general specifications for use in a range of residential, commercial and industrial solar power generation systems.

AK Steel Holding Corporation (NYSE:AKS) declined 3.36%, with the closing price of $3.45. The overall volume in the last trading session was 8.24 million shares. Its fifty two week range was $2.76-$6.73. The total market capitalization remained $470.27 million. Other key statistics show that AKS is ahead of its 52 week low 25.00% and its last month price volatility remained 6.38%. Its beta coefficient was 2.65, with a target price of $4.04. AKS has insider ownership of 11.99% and its institutional ownership remained 15.75%. Company’s current year earnings per share reduced 540.10%, while the five year EPS growth rate was -35.90%.

Dynavax Technologies Corporation (NASDAQ:DVAX) dropped -4.35% and closed at $1.10, with the overall traded volume of 4.51 million shares in the last trading session. DVAX had a day trading range of $1.09-$1.21 and its opening price was $1.18. Dynavax Technologies Corporation (Dynavax), a clinical-stage biopharmaceutical company, discovers and develops products to prevent and treat infectious and inflammatory diseases. Its product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine, designed to provide higher and earlier protection with fewer doses than licensed vaccines.

Comments are closed.